stockportfolio.pro
Medpace Holdings, Inc. (MEDP)
Healthcare · Diagnostics & Research · NasdaqGS
Medpace Holdings, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $421.58M | $436.15M | $704.59M | $860.97M | $925.92M | $1.14B | $1.46B | $1.89B | $2.11B | $2.53B |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $13.43M | $39.12M | $73.19M | $100.44M | $145.38M | $181.85M | $245.37M | $282.81M | $404.39M | $451.12M |
| Net margin | 3.2% | 9.0% | 10.4% | 11.7% | 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
Source: Medpace Holdings, Inc. SEC filings (10-K). 11 years of history available in the interactive view.
What growth is priced into MEDP stock?
At today's market cap of $13.34B, Medpace Holdings, Inc. is priced for free-cash-flow growth of about 7.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $681.87M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 24.6%/yr over the last five fiscal years and revenue 22.3%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 11 years of Medpace Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MEDP in your portfolio →
Medpace Holdings, Inc. financial history by metric
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Medpace Holdings, Inc. — frequently asked questions
What is Medpace Holdings, Inc.'s revenue?
Medpace Holdings, Inc. (MEDP) reported revenue of $2.53B for fiscal year 2025, up 20.0% from the prior year, according to its SEC filings.
Is Medpace Holdings, Inc. profitable?
Yes. MEDP earned net income of $451.12M in fiscal 2025, a net margin of 17.8%.
What is MEDP's P/E ratio?
Medpace Holdings, Inc. trades at a price-to-earnings ratio of about 29.3 based on the latest data in our nightly-refreshed cache.
How fast is Medpace Holdings, Inc. growing?
MEDP's revenue grew at roughly 22.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Medpace Holdings, Inc. have?
As of fiscal year 2025, MEDP carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Medpace Holdings, Inc.'s market cap?
Medpace Holdings, Inc. (MEDP) has a market capitalization of about $13.34B, based on the latest data in our nightly-refreshed cache.
When does Medpace Holdings, Inc.'s fiscal year end?
MEDP's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into MEDP stock?
At today's market cap of $13.34B, Medpace Holdings, Inc. is priced for free-cash-flow growth of about 7.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $681.87M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 24.6%/yr over the last five fiscal years and revenue 22.3%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Medpace Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.